Science

Articles

• Vect-Horus appoints Claudia Fromond as new Director of R&D
  10 March, by Emmanuelle BETTENDORF

  We are very pleased to welcome Claudia Fromond to Vect-Horus as our new Director of R&D.
  Claudia is a highly regarded pharmacology and translational science leader with extensive experience in R&D. She has successfully overseen first-in-class programs from discovery to Investigational New Drug (IND) application and early clinical development, including a portfolio of seven IND-enabling programs which achieved Phase 1/2 readiness.
  “Claudia has a proven track record of successfully (…)

• Harnessing TfR1 for Cross-Species Systemic Delivery of siRNAs to Deep Brain Regions Using Single-Domain Antibodies
  26 May, by Emmanuelle BETTENDORF

  Our latest preprint demonstrating the ability of the VECTrans® platform to deliver therapeutics, particularly oligonucleotides, to deep regions of the brain at clinically viable doses has just been published by bioRxiv.
  The research by @Guillaume Jacquot and the Vect-Horus team details the unique functions of our technology platform to transport oligonucleotides across the blood-brain barrier and open up new avenues for the treatment of diverse central nervous system disorders. (…)

• Meet Vect-Horus at Deeptech in Glioblastoma Symposium
  13 January, by Emmanuelle BETTENDORF

  Cédric Malicet, our Oncology Program Director, will be taking part in a panel discussion at the DeepTech in Glioblastoma conference, organized by Paris Saclay Cancer Cluster (PSCC), and taking place January 22 in Villejuif, France.
  Cedric will participate in a pitch session entitled “A comprehensive and diverse front against glioblastoma”, along with representatives from Carthera, TheraSonic, Robeauté, Innov’nCare , with the discussion moderated by Professor Ahmed Idbaih .
  It takes place (…)

• Vect-Horus Publication in Pharmaceutics Outlines How Vectors Can Improve Delivery of Therapeutics to Organs and Tumors
  22 April 2024, by Emmanuelle BETTENDORF

  Marseille, France, April 22 - Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the publication of a paper in the open-access scientific journal Pharmaceutics Vol 26 (MDPI).
  The paper, entitled “LDLR-Mediated Targeting and Productive Uptake of siRNA-Peptide Ligand Conjugates In Vitro and In Vivo”, outlines a study which showed how peptides (…)

• How blood–brain barrier technology is unleashing CNS therapies
  19 September 2025, by Emmanuelle BETTENDORF

  Nature Research has republished an in-depth article on Vect-Horus in the September issue of Biopharma Dealmakers. The issue focuses on CNS related technologies and therapeutics.
  It’s well worth having a read, or re-read, of this piece, which outlines our VECTrans platform and its potential to transform the treatment of neurodegenerative disorders.
  It also touches on the science and data behind our approach and our partnerships with Novo Nordisk Radiomedix, Inc. and Ionis Pharmaceuticals, (…)

• Our latest research article is now available on bioRxiv and medRxiv
  11 July 2025, by Emmanuelle BETTENDORF

  In this study, we explored the identification and optimization of cross-species reactive VHHs (single-domain antibodies from camelids) targeting the transferrin receptor 1 (TfR1) — a promising strategy for delivering therapeutics across the blood-brain barrier.
  We focused on two candidates, C5 and B8, which bind TfR1 in rodents, non-human primates, and humans. These VHHs show potential as molecular shuttles for transporting imaging or therapeutic agents across species — paving the way for (…)

• Meet Vect-Horus at OTS, Barcelona, October 22-25, 2023
  12 October 2023, by Emmanuelle BETTENDORF

  Vect-Horus team will attend the 19th Annual Meeting of the Oligonucleotide Therapeutics Society from October 22nd to 25th, 2023, in Barcelona.
  We are pleased to announce that Guillaume Jacquot, Program Director, Brain & Tissue Targeting of Oligonucleotides, will give a talk entitled “TfR-targeted functional delivery of oligonucleotides to CNS tissues by local and systemic administration” on Tuesday, 24th and Emmanuelle Bettendorf, Senior Business Developer, will also be there and (…)

• Vect-Horus Strengthens Board of Directors with Appointment of Jean-Christophe Dantonel as New Member
  14 November 2024, by Emmanuelle BETTENDORF

  We’re pleased to welcome Jean-Christophe Dantonel as a new member of the Vect-Horus Board of Directors!
  Dr. Dantonel brings over two decades of profound expertise in biological sciences, project management, and clinical research to his new role.
  “He brings key skills to our company at an important stage of its development, with a combination of clinical research and business experience which will be invaluable as we innovate to develop vectors that facilitate targeting and delivery of (…)

• AD/PD 2019​ International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders in LISBON
  28 January 2019, by Jonathan NOWAK

  Marion DAVID and Romy COHEN will present the “Development of vectors that cross the blood brain barrier to enhance CNS drug delivery in neurodegenerative diseases” in session A: β-Amyloid Diseases poster n°ADPD9-1832

• Vect-Horus demonstrates the high versatility of its peptide-vectors library for a targeted delivery of small molecules and protein cargos
  28 January 2019, by Jonathan NOWAK

  Identification and characterization of highly versatile peptide-vectors that bind non-competitively to the low-density lipoprotein receptor for in vivo targeting and delivery of small molecules and protein cargos.
  Marion David, Pascaline Lécorché, Maxime Masse, Aude Faucon, Karima Abouzid, Nicolas Gaudin, Karine Varini, Fanny Gassiot, Géraldine Ferracci, Guillaume Jacquot, Patrick Vlieghe, Michel Khrestchatisky
  http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0191052 (…)